Kwyktel Beta 25 Tablet ER is a combination antihypertensive medication containing Telmisartan 40 mg and Metoprolol Succinate 25 mg in an extended-release formulation. Telmisartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Metoprolol Succinate is a cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and improved cardiac function. The extended-release formulation ensures a sustained therapeutic effect, allowing once-daily dosing and improved patient compliance. Kwyktel Beta 25 is indicated for the management of hypertension, particularly in patients who require combined therapy for optimal blood pressure control. It may also be beneficial in patients with concomitant cardiovascular conditions such as ischemic heart disease or heart failure where beta-blockade is indicated. Caution is advised in patients with bradycardia, heart block, or severe hepatic impairment. Common adverse effects include dizziness, fatigue, and hypotension. Regular monitoring of blood pressure, renal function, and electrolytes is recommended during therapy. Kwyktel Beta 25 should be used under medical supervision with appropriate dose adjustments based on clinical response.